| Autor: |
Yi-Wen Huang, Ming-Chih Yu, Chih-Bin Lin, Jen-Jyh Lee, Chou-Jui Lin, Shun-Tien Chien, Chih-Hsin Lee, Chen-Yuan Chiang |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Journal of Microbiology, Immunology and Infection, Vol 57, Iss 4, Pp 617-628 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
1684-1182 |
| DOI: |
10.1016/j.jmii.2024.04.008 |
| Popis: |
Background: Pre-extensively drug-resistant tuberculosis (pre-XDR-TB), defined as multidrug-resistant TB (MDR-TB) with additional resistance to any fluoroquinolone (FQ) is difficult to treat. We assessed whether the use of new or repurposed drugs (bedaquiline, delamanid, linezolid, carbapenem, clofazimine, pretomanid) mitigated treatment failure of pre-XDR-TB. Methods: MDR-TB patients managed in the Taiwan MDR-TB consortium between July 2009–December 2019 were eligible. Treatment outcomes at 30 months were assessed. Logistic regression models were constructed to investigate factors associated with treatment outcomes. Results: 109 patients with FQ-resistant MDR-TB and 218 patients with FQ-susceptible MDR-TB were included. 60 (55.1%) patients with FQ-resistant MDR-TB and 63 (28.9%) patients with FQ-susceptible MDR-TB have been treated with new or repurposed drugs (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
